Annette M Lim

8PUBLICATIONS
29CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Molecular targetsHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 24, 2026
Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final Analysis.

|Oct 15, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.

Ling Zhu, Yee-Ming M Cheung, Cherie Chiang

|Oct 11, 2025
A two-phase study investigating the quality of life benefit of additional 0.5% cocaine mouthwash to institutional standard of care mucositis management in head and neck cancer patients undergoing radiotherapy or chemoradiotherapy.

Piyush Grover, Colin Tang, Angela Jacques

|Aug 27, 2025
Impact of Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma.

Annette M Lim, Sandro Porceddu, Danny Rischin

|Apr 27, 2024
A Retrospective Review and Comprehensive Tumour Profiling of Advanced Non-Melanomatous Cutaneous Spindle Cell Neoplasms Treated with Immune-Checkpoint Inhibitors.

Luke S McLean, Annette M Lim, Christopher Angel

|Nov 27, 2021
Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma.

Alesha A Thai, Annette M Lim, Benjamin J Solomon

Pageof 2

Frequent Collaborators

3 joint publications

Danny Rischin

2 joint publications

Piyush Grover

1 joint publications

Stephanie Flukes

1 joint publications

Angela Jacques